Seres Therapeutics, Inc.
MCRB · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $145 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | $4 | $0 | $0 | $0 |
| Gross Profit | -$4 | $0 | $0 | $145 |
| % Margin | – | – | – | 100% |
| R&D Expenses | $65 | $118 | $110 | $142 |
| G&A Expenses | $53 | $78 | $70 | $69 |
| SG&A Expenses | $53 | $78 | $70 | $69 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | -$2 |
| Operating Expenses | $118 | $195 | $180 | $209 |
| Operating Income | -$121 | -$195 | -$180 | -$64 |
| % Margin | – | – | – | -44.5% |
| Other Income/Exp. Net | -$4 | $5 | -$4 | -$1 |
| Pre-Tax Income | -$126 | -$190 | -$184 | -$66 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | $0 | -$114 | -$250 | -$66 |
| % Margin | – | – | – | -45.2% |
| EPS | -18.864 | -17.769 | -46.292 | -14.302 |
| % Growth | -6.2% | 61.6% | -223.7% | – |
| EPS Diluted | -18.864 | -17.769 | -46.292 | -14.302 |
| Weighted Avg Shares Out | 8 | 6 | 5 | 5 |
| Weighted Avg Shares Out Dil | 8 | 6 | 5 | 5 |
| Supplemental Information | – | – | – | – |
| Interest Income | $4 | $7 | $3 | $3 |
| Interest Expense | $0 | $13 | $6 | $3 |
| Depreciation & Amortization | $5 | $6 | $7 | $6 |
| EBITDA | -$120 | -$181 | -$171 | -$57 |
| % Margin | – | – | – | -39.1% |